Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Overview of Affimed N.V.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of targeted immuno-oncology therapies. With a rigorous scientific approach, the company leverages its proprietary ROCK® platform to generate innovative, tetravalent, bispecific antibodies known as tandAbs®. These agents are designed to engage key immune cells, such as natural killer (NK) cells and T-cells, and direct them toward tumor cells, thereby triggering a robust immunologic response against both hematologic and solid tumors. Early-stage clinical candidates are advancing through various phases with a clear emphasis on efficacy and manageable safety profiles.
Core Technology and Mechanism
The foundation of Affimed's approach lies in its capability to harness the body's innate immune defense mechanisms. By developing bispecific molecules that target both immune effector cells and cancer cells, Affimed creates a 'bridge' that facilitates a potent antibody-dependent cellular cytotoxicity response. The unique tetravalent architecture means that these tandAbs® possess four binding domains, enabling high affinity interactions with both the immune and tumor cell surfaces. This design not only assures precise targeting but also allows for the dosing flexibility required in clinical applications, as these agents can be administered via standard intravenous infusions.
Product Pipeline and Innovations
Affimed's pipeline includes multiple candidates developed to address a range of challenging cancer indications. The company is actively involved in the preclinical and clinical development of several innovative product candidates, such as those targeting antigens on both blood cancers and solid tumors. For instance, candidates like its CD123- and CD16A-binding molecules are designed with a dual mechanism that recruits NK cells to eliminate malignant cells effectively. The integration of these molecules into combinatorial therapies further exemplifies the company's pursuit of expanded clinical applicability.
Revenue Model and Market Significance
In addition to its clinical development efforts, Affimed generates revenue from delivering research and development services. These services are based on both group-owned and third-party intellectual property, highlighting a diversified approach that complements its core therapeutic innovations. The company's operational reach extends across strategic markets, notably in the United States and Europe, ensuring a broad impact within the dynamic biopharmaceutical environment.
Competitive Landscape and Differentiation
Affimed stands out in the competitive immuno-oncology space by virtue of its distinctive methodology and proprietary technology. Unlike traditional antibody therapies, its focus on engaging innate immune cells through a sophisticated bispecific mechanism establishes a strong competitive differentiation. This nuanced approach, combined with active collaborations and a commitment to rigorous clinical evaluation, reinforces its position as a significant player in advancing cancer immunotherapies. The company's strategic emphasis on both monotherapy and combination therapy regimens addresses unmet patient needs without oversimplifying the underlying science.
Scientific Rigor and Industry Expertise
Throughout its operations, Affimed demonstrates deep scientific and clinical expertise. The careful engineering of its molecules, alongside a clear understanding of antibody kinetics and immune cell activation, underscores its commitment to delivering precision-based oncology treatments. The company’s ongoing trials, regulatory milestones, and adaptive clinical strategies further illustrate its role not just as a developer of targeted therapies, but as an innovator in the broader biopharmaceutical industry.
Summary
- Clinical-Stage Focus: Engaged in advanced clinical development of targeted immuno-oncology therapies.
- Innovative Technology: Utilizes a proprietary ROCK® platform to develop four-binding-domain bispecific antibodies.
- Dual Mechanism: Designed to recruit and activate innate immune cells for effective tumor cell killing.
- Revenue Streams: Generates income through R&D services leveraging both proprietary and third-party intellectual property.
- Global Presence: Operates in key markets including the United States and Europe.
- Scientific Expertise: Combines robust clinical trials with advanced biotechnological innovation, ensuring an in-depth approach to cancer immunotherapy.
This comprehensive profile of Affimed N.V. outlines the company's mission to transform cancer treatment by activating the body's innate defenses. It reflects a deep understanding of the industry, advanced scientific methodologies, and a differentiated business model that positions the company as an influential contributor to the evolving landscape of cancer immunotherapy.
Affimed N.V. (Nasdaq: AFMD) announced promising preclinical results for AFM13, an innate cell engager (ICE®) targeting CD30-positive tumors. The data showed that AFM13 enhanced the efficacy of natural killer (NK) cells in recognizing and killing tumor cells both in vitro and in vivo. This supports the ongoing Phase I clinical trial of AFM13 pre-complexed with NK cells. Notably, early Phase 1 data revealed a 100% objective response rate among heavily pretreated patients, with no severe side effects reported. These findings highlight AFM13's potential as an innovative cancer treatment.
Affimed N.V. (Nasdaq: AFMD) reported positive interim results for its AFM13 monotherapy study in PTCL, achieving a 100% objective response rate in four evaluable patients, including two complete responses. The company also provided updates on clinical trials for AFM24, including a cleared IND application for its combination with NKGen's SNK-01. Financially, Affimed showed a pro forma cash position of approximately €244.5 million as of December 31, 2020, which supports operations through mid-2023. Total revenue rose to €28.4 million in 2020, driven largely by collaborations with Genentech and Roivant.
Affimed N.V. (Nasdaq: AFMD) has announced promising pre-clinical data for its Innate Cell Engager (ICE®) AFM24, demonstrating significant tumor cell killing capabilities independent of KRAS mutations. Presented at the AACR Virtual Annual Meeting, AFM24 shows potential in combination with adoptively transferred NK cells, leading to dose-dependent tumor regression. This innovative mechanism may change the treatment landscape for EGFR-expressing solid tumors. The company continues to evaluate AFM24 for patients with advanced malignancies, supported by regulatory approvals for ongoing clinical trials.
Affimed N.V. (Nasdaq: AFMD) announced promising initial results from a Phase 1 trial at MD Anderson, showcasing a 100% objective response rate in four patients with recurrent/refractory CD30-positive lymphomas. Among these, two achieved complete responses and two had partial responses. Importantly, there were no signs of cytokine release syndrome or neurotoxicity. The trial, which utilizes cord blood-derived NK cells pre-complexed with Affimed's AFM13, is continuing to enroll patients for further cohorts. A conference call is scheduled for April 14 to discuss these findings.
Affimed N.V. (Nasdaq: AFMD) will report its 2020 financial results and corporate updates on April 15, 2021, with a conference call at 8:30 a.m. EDT. Investors can join via phone or webcast, accessing the call with specific dial-in numbers and a conference ID.
Affimed is focused on immuno-oncology, leveraging its proprietary ROCK® platform to develop therapies aimed at treating various tumors. The company aims to empower patients' innate immunity to combat cancer effectively.
Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc. announced the FDA's clearance of an IND for a Phase 1/2a study. This trial will explore the combination of AFM24, an EGFR/CD16A innate cell engager, with SNK-01, an autologous NK-cell product, targeting solid tumors expressing EGFR. The aim is to improve treatment outcomes for patients who have failed conventional therapies. The study will assess safety, pharmacokinetics, and preliminary efficacy, marking a significant step for both companies in advancing innate immunity-based therapies.
Affimed N.V. (Nasdaq: AFMD) announced that preclinical data on AFM24 will be showcased via e-poster at the AACR Virtual Annual Meeting I from April 10-15, 2021. The poster presents AFM24 as a potent bispecific innate cell engager targeting EGFR for cancer treatment. Additionally, AFM13 data will be highlighted in a symposium on April 13, focusing on its use in combination with NK cells for treating CD30-expressing lymphomas. These presentations aim to advance understanding of the efficacy of these therapies in oncology.
Affimed N.V. (Nasdaq: AFMD) has decided to continue enrollment in its REDIRECT trial evaluating AFM13 for treating relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) following a preplanned interim futility analysis. The analysis showed that the response rate in Cohort A qualified for continuation, and Cohorts A and B will merge for further evaluation. Objective responses were observed in heavily pretreated patients with a safety profile consistent with prior trials. An investor conference call is scheduled for March 10, 2021, at 8:30 a.m. EST.
Affimed N.V. (Nasdaq: AFMD) announced a collaboration with Roche to explore AFM24, its innate cell engager, in combination with Roche’s PD-L1 inhibitor atezolizumab for treating patients with advanced solid tumors expressing EGFR. The Phase 1/2a clinical trial will assess safety and efficacy, funded and conducted by Affimed with Roche supplying atezolizumab. This partnership aims to leverage the potential synergistic effects of AFM24 and PD-(L)1 inhibition. Previous studies suggest promising safety and activity profiles for AFM24 in preclinical settings.
Affimed N.V. announced the completion of its public offering of 19,166,667 common shares at a price of $6.00 per share, raising $115 million in gross proceeds. This includes the underwriters' full exercise option for an additional 2,500,000 shares. The offering underlines Affimed's commitment to advancing its immuno-oncology pipeline, which includes therapies for hematologic and solid tumors. Despite the capital raised, potential risks associated with the offering and market conditions remain.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
What is the primary focus of Affimed N.V.?
How does Affimed's technology work?
What products or therapies are in Affimed's pipeline?
How does Affimed generate revenue?
What distinguishes Affimed from its competitors?
In which markets does Affimed operate?
What are the advantages of the company’s tetravalent antibody architecture?
How does Affimed contribute to advancing immuno-oncology?
